Discover & Learn

Discover our tailor-made radiopharmacy solutions, and connect with our experts at booth #2023.

IBA specialists are available to discuss cyclotron and radiochemistry technologies, as well as integrated solutions.

This is an opportunity to exchange on ongoing projects, technical challenges and future development plans in radioisotope production.

At Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine, discover our end‑to‑end radiopharmacy solutions, from cyclotrons to radiochemistry, designed for reliable production.

Let’s exchange on your projects and challenges, and what comes next.

Discover our end‑to‑end radiopharmacy solutions, designed for reliable production.

Let’s exchange on your projects and challenges, and what comes next.

Before setting up an in-house radiopharmacy, the CHU Québec – Université Laval relied on external providers for radiopharmaceuticals. It constrained its ability to provide patient access to novel theranostics radiopharmaceuticals. The Canadian hospital turned to IBA for a solution that could ensure consistent and flexible production while supporting both clinical care and research.

In nuclear medicine, some molecules don’t just gather intelligence, they also act. A theranostic is a double agent inside the body. It works as radiopharmaceuticals, finding the right “lock” to reach abnormal cells. But it carries a second mission: not only to reveal hidden threats, but also to strike them directly.
 

The first part of its mission is diagnostic. Guided by its biological GPS, the molecule locates its target, often a tumor, and emits a signal detected by scanners. It undercovers the hidden activity inside the body, creating a precise molecular map that shows exactly where the disease is.

Building a radiopharmacy is like building a fortress for molecules. Every wall, every corner, every piece of equipment is carefully engineered to protect people, safeguard radioactive materials, and produce high-quality medicines.
 

The first step is to define what the fortress is built for. What types of radiopharmaceuticals will it produce: diagnostic, therapeutic, or both? Will it serve a single hospital or an entire network?